Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.38) per share.
Canaccord Genuity Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6
Canaccord Genuity analyst Richard Close initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Buy rating and announces Price Target of $6.